提高单体的药理动力学,生物分布和血稳定性
Adrian Valentin Dinh-Fricke1, Oliver Hantschel1
1Institute of Physiological Chemistry, Philipps-University of Marburg, Marburg, Germany.
Frontiers in pharmacology
|April 15, 2024
概括
单体显示出癌症治疗的希望,但其半衰期很短. 将它们与专蛋白结合域 (ABD) 融合,延长了它们在体内存在的时间,增强了它们作为新型细胞内癌症治疗的潜力.
科学领域:
- 生物技术是生物技术.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症仍然是导致死亡的主要原因,治疗耐药性和转移构成重大挑战.
- 针对性抗癌药物,就像治疗性抗体一样,仅限于细胞外点.
- 单体是为细胞内点设计的蛋白质结合剂,但它们的治疗潜力尚未被探索.
研究的目的:
- 为了研究单体的药理性质,用于癌症治疗.
- 设计具有改善药物动力学配置的单体,以提高治疗疗效.
- 评估基于单体的治疗方法对细胞内癌症标的潜力.
主要方法:
- 在体内评估单体的血稳定性,毒性和药理动力学.
- 工程化单体融合与蛋白结合域 (ABD).
- 评估了ABD-单体融合的药理动力学特性和向结合.
主要成果:
- 单体具有很高的血稳定性,在小鼠中耐受性很好,但由于脏清除速度快,体内半衰期很短.
- 在ABD-单体融合中,血稳定性增加,并显著延长了体内半衰期.
- 而ABD单体的分泌速度不快,也不会在特定的器官中积累,从而保持目标结合.
结论:
- 单体是开发新型细胞内癌症疗法的有希望的支架.
- 具有蛋白结合域 (ABD) 的工程单体显著增强了它们的药理动力学特性.
- ABD-单体融合为准细胞内coproteins和改善癌症患者的治疗结果提供了一个多功能平台.
相关概念视频
Drug Distribution: Plasma Protein Binding
5.5K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.5K
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
164
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
164
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Biopharmaceutics and Pharmacokinetics: Overview
2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
202
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
202
Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K


